Efficacy of standard dose rituximab for refractory idiopathic thrombocytopenic purpura in children

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 13, 2015, Pages 2379-2383

  Dai, W J ^a   Zhang, R R ^b   Yang, X C ^b   Yuan, Y F ^b  

^a YANGZHOU UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Children; Efficacy; Idiopathic thrombocytopenic purpura; Rituximab; Standard dose

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; IMMUNOGLOBULIN; RITUXIMAB; VINCRISTINE; IMMUNOLOGIC FACTOR;

ADOLESCENT; ARTICLE; B LYMPHOCYTE; CHILD; CHILD HOSPITALIZATION; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HEMATOLOGY ANALYZER; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFANT; INFECTION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; PHYSICAL EXAMINATION; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENCE RISK; REFRACTORY IDIOPATHIC THROMBOCYTOPENIC PURPURA; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; DRUG EFFECTS; PRESCHOOL CHILD; PROCEDURES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENT DISEASE; REMISSION; THROMBOCYTE; TREATMENT OUTCOME;

ADOLESCENT; B-LYMPHOCYTES; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INFANT; MALE; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENCE; REMISSION INDUCTION; RITUXIMAB; TREATMENT OUTCOME;

EID: 84942246115     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. BERNADETTE G. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008;141:149-169.
2. MOTOHIRO K, KATSUYOSHI K, AKIRA K, RYOJI H. Spontaneous improvement of chronic immune thrombocytopenia in children: experience of 56 patients at a single institute. Int J Hematol 2012;96:729-732.
3. ZHANG C, LIU HF, CHEN XH, GAO L, GAO L, LIU Y, KONG PY, SUN AH, ZHANG X. Is Splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience. Clin Ther 2014;36:385-388.
4. WANG J, WILEY JM, LUDDY R, GREENBERG J, FEUERSTEIN MA, BUSSEL JB. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 2005;146:217-221.
5. TAUBE T, SEHMID H, REINHARD H, VON STACKELBERG A, OVERBERG US. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologiea 2005;90:281-283.
6. BAY A, ONER AF, UNER A, DOGAN M. Use of rituximab in chronic childhood immune thrombocytopenic purpura. Pediatr Int 2006;48:514-516.
7. BENNETT CM, ROGERS ZR, KINNAMON DD, BUSSEL JB, MAHONEY DH, ABSHIRE TC, SAWAF H, MOORE TB, LOH ML, GLADER BE, MCCARTHY MC, MUELLER BU, OLSON TA, LORENZANA AN, MENTZER WC, BUCHANAN GR, FELDMAN HA, NEUFELD EJ. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006;107:2639-2642.
8. MOSCHOVI M, TRIMIS G, PERGANTOU H, PLATOKOUKI H, VRACHNOU E, TZORTZATOU-STATHOPOULOU F. Clinical remission following monoclonal anti-CD20 therapy in two children with chronic refractory idiopathic thrombocytopenic purpura. J Paediatr Child Health 2005;41:384-386.
9. JULIE W, JOSEPH MW, RUTH L, JAY G, MICHAEL AF, JAMES BB. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 2005;146:217-221.
10. BENNETT CM, ROGERS ZR, KINNAMON DD, BUSSEL JB, MAHONEY DH, ABSHIRE TC, SAWAF H, MOORE TB, LOH ML, GLADER BE, MCCARTHY MC, MUELLER BU, OLSON TA, LORENZANA AN, MENTZER WC, BUCHANAN GR, FELDMAN HA, NEUFELD EJ. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006;107:2639-2642.
11. PATEL VL, MAHÉVAS M, LEE SY, STASI R, CUNNINGHAMRUNDLES S, GODEAU B, KANTER J, NEUFELD E, TAUBE T, RAMENGHI U, SHENOY S, WARD MJ, MIHATOV N, PATEL VL, BIERLING P, LESSER M, COOPER N, BUSSEL JB. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012;119:5989-5995.
12. KELLY K, GLEESON M, MURPHY PT. Slow responses to standard dose rituximab in immune thrombocytopenic purpura. Haematologica 2009;94:443-444.
13. GÓMEZ-ALMAGUER D, TARÍN-ARZAGA L, MORENO-JAIME B, JAIME-PÉREZ JC, CEBALLOS-LÓPEZ AA, RUIZ-ARGÜELLES GJ, RUIZ-DELGADO GJ, CANTÚ-RODRÍGUEZ OG, GUTIÉRREZ-AGUIRRE CH, SÁNCHEZ-CÁRDENAS M. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol 2013;90:494-500.
14. FRIEDBER JW. Unique toxieities and resistance mechanisms associated with monoelonal antibody therapy. Hematology Am Soc Hematol Educ Program 2005;329-334.
15. SMITH MR. Rituximab (Monoelonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-7368.
16. MONTOYA RC, POIESZ BJ. Rituximab as prophylaxis in chronic relapsing thrombotic thrombocytopenic purpura: a case report and review of the literature. Blood Coagul Fibrinolysis 2012;23:338-41.
17. COOPER N, BUSSEL JB. The long-term impact of rituximab for childhood immune thrombocytopenia. Curr Rheumatol Rep 2010;12:94-100.